|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Non-Neoplastic Urinary System Disorder
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
LAPSER1: a novel candidate tumor suppressor gene from 10q24.3.
|
11709705 |
2001 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
LAPSER1 is expressed at the highest levels in normal prostate and testis, where multiple isoforms are seen, some of which are either undetectable or differentially expressed in some prostate tumor tissues and cell lines.
|
11709705 |
2001 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.
|
17351128 |
2007 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.
|
17351128 |
2007 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.
|
17351128 |
2007 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
LZTS2 (leucine zipper tumor suppressor 2), a candidate tumor suppressor gene, suppresses cell growth and plays a vital role in the carcinogenesis and development of tumors.
|
29499699 |
2018 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of PTEN and LZTS2 in prostate cancer cells shows stronger repressive effect on ß-catenin mediated transcription.
|
28323888 |
2017 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of PTEN and LZTS2 in prostate cancer cells shows stronger repressive effect on ß-catenin mediated transcription.
|
28323888 |
2017 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells.
|
23275340 |
2013 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Examination of human prostate cancer tissue specimens shows a reduction of LZTS2 protein expression in prostate cancer cells.
|
23275340 |
2013 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Functionally, we showed that LZTS2 suppresses tumorigenesis and radioresistance in nasopharyngeal carcinoma in a p85-dependent manner.
|
29409973 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, LZTS2 methylation levels were elevated in smokers, advanced T classified, and clinically staged patients, as well as in patients with lymph node metastases.
|
29499699 |
2018 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In conclusion, our results demonstrate the critical role of miR-300 in GSLCs and its functions in LZTS2 inhibition and describe a new approach for the molecular regulation of tumor stem cells.
|
24464870 |
2014 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
|
17351128 |
2007 |
|
Deformity
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
|
17351128 |
2007 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
No studies to date have described methylation of the LZTS2 promoter in human cancers, including LSCC (laryngeal squamous cell carcinoma).
|
29499699 |
2018 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results not only provide understanding of the molecular mechanisms by which PI3K/AKT signaling is activated but also suggest that targeting the LZTS2/PI3K/AKT signaling axis is a promising therapeutic strategy for radiosensitization of nasopharyngeal carcinoma.
|
29409973 |
2018 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
The LZTS2 gene is located at 10q24.3, which is frequently lost in a variety of human tumors.
|
17000760 |
2006 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The leucine zipper tumor suppressor 2 (LZTS2) was identified as a tumor susceptibility gene within the 10q24.3 chromosomal region, and is approximately 15Mb from the PTEN locus.
|
28323888 |
2017 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
The qMSP analyses revealed that LZTS2 promoter methylation levels in the LSCC tumor samples were significantly higher than those in paired adjacent healthy tissue samples.
|
29499699 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrate the significance of simultaneous Pten and Lzts2 deletion in oncogenic transformation in prostate cells and implicates a new mechanism for the dysregulation of Wnt/β-catenin signaling in prostate tumorigenesis.
|
28323888 |
2017 |
|
Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
These data provide the first line of evidence demonstrating that deletion of Lzts2 increases susceptibility to spontaneous and carcinogen-induced tumor development.
|
23275340 |
2013 |